These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 26104108)
21. [Myositis and the skin: cutaneous manifestations of dermatomyositis]. Jinnin M Brain Nerve; 2013 Nov; 65(11):1283-90. PubMed ID: 24200606 [TBL] [Abstract][Full Text] [Related]
22. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Dalakas MC Curr Opin Neurol; 2004 Oct; 17(5):561-7. PubMed ID: 15367860 [TBL] [Abstract][Full Text] [Related]
23. New developments in the role of cytokines and chemokines in inflammatory myopathies. Lundberg IE; Nyberg P Curr Opin Rheumatol; 1998 Nov; 10(6):521-9. PubMed ID: 9812212 [TBL] [Abstract][Full Text] [Related]
24. Polymyositis: not a unicorn or mythological beast...but maybe a duck? Kissel JT Neurology; 2008 Feb; 70(6):414-5. PubMed ID: 18250286 [No Abstract] [Full Text] [Related]
29. A dual role for HSP90 and HSP70 in the inflammatory myopathies: from muscle fiber protection to active invasion by macrophages. De Paepe B; Creus KK; Martin JJ; Weis J; De Bleecker JL Ann N Y Acad Sci; 2009 Sep; 1173():463-9. PubMed ID: 19758187 [TBL] [Abstract][Full Text] [Related]
30. Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. Sallum AM; Kiss MH; Silva CA; Wakamatsu A; Vianna MA; Sachetti S; Marie SK Autoimmun Rev; 2006 Feb; 5(2):93-100. PubMed ID: 16431335 [TBL] [Abstract][Full Text] [Related]
31. Diagnostic criteria for polymyositis and dermatomyositis. Miller FW; Rider LG; Plotz PH; Isenberg DA; Oddis CV Lancet; 2003 Nov; 362(9397):1762-3; author reply 1763. PubMed ID: 14643132 [No Abstract] [Full Text] [Related]
32. Inflammatory myopathies: evaluation and management. Greenberg SA Semin Neurol; 2008 Apr; 28(2):241-9. PubMed ID: 18351525 [TBL] [Abstract][Full Text] [Related]
33. Current Classification and Management of Inflammatory Myopathies. Schmidt J J Neuromuscul Dis; 2018; 5(2):109-129. PubMed ID: 29865091 [TBL] [Abstract][Full Text] [Related]
34. Transforming growth factor-β signaling is upregulated in sporadic inclusion body myositis. Noda S; Koike H; Maeshima S; Nakanishi H; Iijima M; Matsuo K; Kimura S; Katsuno M; Sobue G Muscle Nerve; 2017 May; 55(5):741-747. PubMed ID: 27623743 [TBL] [Abstract][Full Text] [Related]
35. Gain and loss of extracellular molecules in sporadic inclusion body myositis and polymyositis--a proteomics-based study. Doppler K; Lindner A; Schütz W; Schütz M; Bornemann A Brain Pathol; 2012 Jan; 22(1):32-40. PubMed ID: 21672074 [TBL] [Abstract][Full Text] [Related]
36. Dermatomyositis. Diagnosis and evaluation of dermatomyositis, polymyositis, and inclusion-body myositis. Krajnc I Adv Exp Med Biol; 1999; 455():181-6. PubMed ID: 10599341 [TBL] [Abstract][Full Text] [Related]
37. The three groups of polymyositis. Serratrice G Rev Rhum Engl Ed; 1996 Dec; 63(11):797-800. PubMed ID: 9010966 [No Abstract] [Full Text] [Related]
38. Activated IL-22 pathway occurs in the muscle tissues of patients with polymyositis or dermatomyositis and is correlated with disease activity. Ciccia F; Rizzo A; Alessandro R; Guggino G; Maugeri R; Saieva L; Cannizzaro A; Giardina A; De Leo G; Gerardo Iacopino D; Triolo G Rheumatology (Oxford); 2014 Jul; 53(7):1307-12. PubMed ID: 24599919 [TBL] [Abstract][Full Text] [Related]
39. Pathophysiology of inflammatory and autoimmune myopathies. Dalakas MC Presse Med; 2011 Apr; 40(4 Pt 2):e237-47. PubMed ID: 21411269 [TBL] [Abstract][Full Text] [Related]
40. The geoepidemiology of autoimmune muscle disease. Prieto S; Grau JM Autoimmun Rev; 2010 Mar; 9(5):A330-4. PubMed ID: 19906360 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]